… devoted some funds to this new area of investment but it took over a decade before the sector started to produce results. ETFs IBB and XBI naturally were to follow but not until early in the last decade. Initial investors in the area were too soon and many …
… the markets over the past 60 days the biotechnology sector has barely flinched and is currently at YTD highs. Bellwether ETFs IBB (126) and XBI ($82.85) are up over 20% YTD after a brief correction in mid-April compared to the S&P which has sold …
By Tom Lydon : Strong prospects for new drug approvals, a favorable M&A environment, and a positive fundamental outlook have the biotechnology industry looking healthy, according to S&P Capital IQ. Investors who want exposure to the overall sector should consider exchange traded funds to help ...
… Vertex's ( VRTX ) cystic fibrosis treatment - and because some investors are betting on deals occurring. One ETF that is doing particularly well this year is iShares Nasdaq Biotech ( IBB ). Others include XBI , FBT and BBH . Post your comment!
By David Pinsen : In a recent blog post ("Can The Crowd Be More Patient?"), venture capitalist Fred Wilson explained the challenge of attracting early equity investment to drug discovery: One of the most noticeable changes to the VC business over the past decade is the movement of investment ...
By Robert Hallberg : A lot of progress has been made in the field of biotechnology and biomedicine since the completion of the human genome projects in 2003. The completion of this project was a huge milestone, and it was supposed to usher in a new era of genetic medicine with new cures. But ...
By David Fry ( ETF Digest ): Biotech sector ETFs have seen recent outperformance primarily due to recent M&A activity particularly with Human Genome Sciences ( HGSI ). Perhaps more importantly there exists the prevailing belief there will be more - not less - of this activity. It's cheaper for ...
By Tom Lydon : Coming off the hopeful drug trial tests and lucrative takeover bids, the biotech sector and related exchange traded funds that follow the industry surged this week. However, some biotechnology ETFs are doing better than the others. The large biotech firms are flush with cash and the
… Biotechnology Index FBT (0.60%), iShares Nasdaq Biotechnology IBB (0.48%), and Market Vectors ..... traditional cap-weighted exposure, IBB is one option, tracking an index ..... market cap of $7.3 billion. IBB also offers the broadest diversification …
… largest and most liquid is iShares Nasdaq Biotechnology IBB , which charges 0.48 ..... of 117 biotech firms. IBB 's portfolio is much ..... a long track record, iShares Nasdaq Biotechnology IBB , has had a volatility …